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Abstract 
 
Available evidence on the impact of ovarian stimulation on endometriosis progression or recurrence 
was systematically reviewed. Data from ovarian stimulation alone or associated to intrauterine 
insemination  (IUI) or in vitro fertilization (IVF) were included.  Sixteen studies were selected. 
Initial case reports (total, 11 patients cases) documented some frightful clinical complications. 
However, subsequent observational studies did not support this alarmism. Overall, five main 
conclusions can be drawn: 1) IVF does not worsen endometriosis-related pain symptoms (moderate 
quality evidence); 2) IVF does not increase the risk of lesion endometriosis recurrence (moderate 
quality evidence); 3) the impact of IVF on ovarian endometriomas is mild, if any (low quality 
evidence); 4) intrauterine insemination may increase the risk of endometriosis recurrence (low 
quality evidence); 5) deep invasive endometriosis might progress with ovarian stimulation (very 
low quality evidence). In conclusion, available evidence is generally reassuring (at least for IVF) 
and does not justify aggressive clinical approaches such as prophylactic surgery before ART to 
prevent endometriosis progression or recurrence. Further evidence is however required for 
definitive conclusions. In particular, the potential effects on deep invasive endometriosis and the 
possible synergic effect of stimulation and pregnancy are two arguments that need to be better 
explored. 
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3 
 
INTRODUCTION 
Endometriosis is a sex hormone-dependent chronic condition that is frequently associated with 
infertility. The prevalence of the disease in the general population has been estimated to be about 1-
2% (Morassuto et al., 2016; Eisenberg et al., 2018) but raises up to 6% to 9% in infertile women 
requiring assisted reproductive technologies (ARTs) (CDC, 2014; Smith et al., 2015). Reasons to 
explain the association between endometriosis and infertility have not been fully clarified, but 
adhesions and the inflammatory pelvic milieu may play a crucial role (Somigliana et al., 2017). 
In recent years, ARTs have become the first-line therapeutic approach to endometriosis-associated 
infertility (Practice Committee ASRM, 2012; Dunselman et al., 2014). However, ARTs are not 
devoid of peculiar drawbacks and harms in this particular population (Somigliana et al., 2015a; 
Somigliana et al., 2015b). Of utmost relevance here is the possibility of disease progression or 
recurrence during or following treatment. Two main reasons support this concern. Firstly, 
peripheral oestrogens that play a fundamental role in endometriosis progression (Vercellini et al., 
2014) considerably raise during ovarian stimulation, reaching levels that are up to ten-folds higher 
than those observed in a physiological natural cycle (Macklon et al., 2006). Secondly, multiple 
ovulations that typically occur during ovarian stimulation could boost the specific risk of 
endometriomas formation. There is indeed growing evidence that endometriomas may originate 
from ovulatory events (Vercellini et al., 2010; Viganò et al., 2013). 
Overall, the possible impact of ovarian stimulation on endometriosis progression or recurrence is 
clinically relevant for both patients and physicians but has received scant consideration in the 
literature, mainly because collecting evidence is methodologically complex. However, some more 
evidence has emerged during the last decade and we deemed that a systematic review of the 
literature on this issue was timely and important.    
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METHODS 
This review was restricted to published research articles that reported on the impact of ovarian 
stimulation on endometriosis in infertile women with the disease. The main outcomes were 
progression (worsening of pain symptoms or growth of endometriotic lesions) or recurrence (onset 
of new pain symptoms, new lesions, need to be operated or to initiate medical therapy).  
Literature overview was conducted according to the PRISMA guidelines for systematic reviews 
(Moher et al., 2009). As published de-identified data were used, this study was exempt from 
institutional review board approval. Data from ovarian stimulation alone, intrauterine insemination 
(IUI) or in vitro fertilization (IVF) could all be included. Conversely, studies exclusively reporting 
on pregnant cases were excluded because discriminating between the detrimental effects of ovarian 
hyper stimulation and pregnancy was not possible. The primary search was conducted with 
Medline, including the time period from January 1990 to January 2018 and using the following 
search strings: (endometriosis OR endometrioma OR endometriotic) AND (in vitro fertilization OR 
IVF OR ICSI OR intracytoplasmatic sperm injection OR intrauterine insemination OR IUI OR 
ovarian hyperstimulation OR ovarian stimulation OR ART OR assisted reproduction technique) 
AND (progression OR recurrence OR complication OR safety). The research was re-checked with 
EMBASE using the PICO system and entering the above-mentioned group of strings for 
Population, Intervention and Outcome, respectively while using the terms expectant management, 
placebo or no treatment for the Comparison category. Published cohort, case-control studies and 
case reports were eligible for inclusion. Studies reporting on complications related to the oocytes 
retrieval procedure itself were excluded. When study periods of studies performed in the same 
Institution overlapped, the smaller one was discarded. Publications not written in English were 
excluded. All pertinent articles were retrieved, and the relative reference lists checked to identify 
further publications. Moreover, the main review articles on endometriosis published over the last 10 
years were consulted and their reference lists searched for potential additional studies. No attempt 
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was made to contact authors for incomplete information and to identify unpublished studies or 
abstracts submitted to national or international conferences. All these researches were conducted 
independently by two of the authors (ES and AB) and discordances were solved by discussion 
including also the other authors if needed. The main measure used was the rate of recurrence. A 
binomial distribution model was used to calculate the 95% Confidence Interval (CI) of proportions. 
 Quality of the case-control or cohort studies was evaluated using the Newcastle Ottawa Scale 
(NOS). This scale gives up to 9 stars to each study and classify them as  low quality (0–4 stars),  
moderate quality (5-6 stars) and high quality (7-9 stars) (Wells et al., 2018). The overall quality of the 
evidence was rated based on the Grading of Recommendation Assessment, Development and Evaluation 
(GRADE) guidelines into four possible categories, i.e. high, moderate, low and very low quality 
(Balshem et al., 2011).   
Data were primary presented according to the study design used (case reports and observational 
studies). Thereafter, they were analyzed taking into consideration separately the ARTs technique 
used (ovarian stimulation alone, IUI and IVF) and the form of the disease (ovarian endometriomas, 
deep peritoneal lesions and  pain symptoms). 
Even if the possibility of combining results into a meta-analysis was initially planned, this analysis 
was ultimately not performed  because of the considerable variability in duration of follow-up, 
study designs and definitions of outcome. 
 
RESULTS 
The flow-chart of the selection process is shown in Figure 1. Overall, sixteen papers were included.  
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Case reports  
The first evidence on the possible detrimental effects of ovarian stimulation on endometriosis 
progression was published in the form of a case report. Specifically, in 1995, Renier et al. 
documented a case of a woman with a history of surgery for endometriosis who was diagnosed with 
left hydronephrosis and complete ureteral stenosis 26 days after the oocytes retrieval. She recovered 
after distal resection of the ureter and bladder re-implantation. The histological examination 
revealed extensive transmural and intramural invasion of the ureter by endometriotic tissue (Renier 
et al., 1995). The good response to ovarian stimulation (12 oocytes retrieved) and the close time-
related occurrence of the event supported a possible causal relation.  
Three subsequent case reports or small case series described 10 additional IVF-related cases. Anaf 
et al. described four women who required segmental bowel resection after IVF, owing to sigmoid 
endometriosis causing severe stenosis of the lumen (Anaf et al., 2000). All women had a surgical 
diagnosis of endometriosis prior to IVF and all had a good response to ovarian stimulation (serum 
oestradiol at the time of ovulation trigger varied between 2,230 and 2,635 pg/ml). The time period 
between the stimulation and the occurrence of the symptoms was not clearly reported, but in at least 
one case this occurred during the stimulation. To note, all these cases were diagnosed with deep 
invasive forms of endometriosis. Jun and Lathi (2007) reported on five women who experienced 
onset or worsening of pelvic pain symptoms during ovarian stimulation for IVF. Two had to 
discontinue the stimulation because of pain. Endometriosis was surgically confirmed after the cycle 
in all cases, with ASRM classification varying between Stage I and IV. Details on the magnitude of 
the responsiveness to ovarian stimulation and on the specific forms of endometriosis detected at 
surgery were not reported.  Finally, Halvorson et al. (2012) described a case of symptomatic 
thoracic endometriosis diagnosed immediately after IVF. The woman developed symptoms 
suggestive for Ovarian Hyper-Stimulation Syndrome (OHSS) three days after the retrieval of 30 
oocytes. She had significant free fluid in the pouch of Douglas and severe bilateral hydrothorax that 
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necessitated bilateral thoracenteses. She then recovered but, after the pregnancy obtained with the 
frozen embryos, she was diagnosed with congenital diaphragmatic agenesis and underwent surgical 
repair that revealed the local presence of endometriosis. On these bases, the authors reinterpreted 
the events occurred at the time of IVF and opted for a final diagnosis of thoracic endometriosis 
syndrome rather than OHSS (Halvorson et al., 2012).  
We failed to identify case reports on endometriosis progression after ovarian stimulation (with or 
without IUI) without IVF. 
 
Case series and cohort studies 
Following the alarm raised by case reports 12 more informative observational studies were 
published (Govaerts et al., 1998; D'Hooghe et al., 2006; Benaglia et al., 2009; Coccia et al., 2010;  
Benaglia et al., 2010; Benaglia et al., 2011; van der Houwen et al., 2014a; van der Houwen et al., 
2014b; van der Houwen et al., 2014c; Crochet et al., 2016; Santulli et al., 2016; Seyhan et al., 
2017). The main characteristics of these studies are shown in Table 1. Five were prospective while 
the remaining seven were retrospective. Six studies were case series of women with endometriosis 
undergoing ARTs (Govaerts et al., 1998; Benaglia et al., 2009; Benaglia et al., 2011; van der 
Houwen et al., 2014a; Santulli et al., 2016; Seyhan et al., 2017). The remaining six fulfilled the 
criteria to be considered cohort studies: three of them included a group of unexposed women with 
the disease who did not undergo ovarian stimulation (Coccia et al., 2010; van der Houwen et al., 
2014b; Crochet et al., 2016) while, in the remaining three, comparisons were made based on a 
gradient of exposure (D'Hooghe et al., 2006; Benaglia et al., 2010; van der Houwen et al., 2014c). 
Of these six studies, two were of moderate quality and four of high quality.  
8 
 
Data on IVF prevailed but some evidence was also available for IUI (D'Hooghe et al., 2006; Coccia 
et al., 2010; van der Houwen et al., 2014c; Crochet et al., 2016). No studies reported on ovarian 
stimulation alone. The definition of recurrence and the duration of follow-up varied widely. 
The crude recurrence rate was reported in ten studies (Govaerts et al., 1998; D'Hooghe et al., 2006; 
Benaglia et al., 2009; Coccia et al., 2010;  Benaglia et al., 2010; Benaglia et al., 2011; van der 
Houwen et al., 2014a; van der Houwen et al., 2014b; van der Houwen et al., 2014c ; Santulli et al., 
2016). Results are summarized in Table 2. The rates varied from 0% to 37%. Combining these 
studies to draw an estimate on the risk of recurrence could not be done given the wide differences in 
durations of follow-up, definitions of recurrences and populations studied (Table 1).  Noteworthy, 
when we plotted rates of recurrences with the mean/median duration of follow-up of the included 
studies, we found a highly significant correlation (Spearman coefficient Rho of 0.86, p=0.001). 
The selected studies did not systematically report on the specific forms of the disease detected at the 
time of recurrence (Table 2). This information was included in only four of them, corresponding to 
24 recurrences (Govaerts et al., 1998; Benaglia et al., 2009; Coccia et al., 2010;  van der Houwen et 
al., 2014a). Deep invasive lesions were diagnosed in 17 of them (71%, 95%CI: 52-86%). In the 
unique available study comparing the type of recurrences between women with endometriosis 
exposed and non-exposed to IVF, deep invasive lesions were documented in 13 (14%) and 8 (9%) 
women, respectively (p=ns) (Coccia et al., 2010). 
Finally, correlation between ovarian responsiveness and risk of recurrence was specifically reported 
in four studies (D’Hooghe et al., 2006; Benaglia et al., 2009; Benaglia et al., 2010; Seyhan et al., 
2018). D’Hooghe et al. (2006) and Seyhan et al. (2018) evaluated the impact of estrogens peak 
levels whereas Benaglia et al. (2009 and 2010) focussed on the number of oocytes retrieved. None 
of these studies identified any statistically significant association.    
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Intrauterine insemination 
D’Hooghe et al. (2006) retrospectively identified 67 women operated for endometriosis stage III-IV 
who subsequently underwent intrauterine insemination (IUI) (n=17), IVF (n=39) or IUI+IVF 
(n=11). The cumulative risks of recurrences at 21 months in the three groups were 84%, 7% and 
43%, respectively. The risk was significantly higher for women undergoing IUI or IUI+IVF 
compared to those receiving IVF (p=0.002 for both). Subsequent evidence on this specific issue is 
not fully consistent. Coccia et al. (2010) failed to show significant differences according to the type 
of ART used: the rates of recurrence in women undergoing IUI (n=34), IVF (n=36) or IUI+IVF 
(n=20) were 18%, 19% and 25%, respectively (p=ns). On the other hand, van der Houwen et al. 
(2014b) provided evidence in support of D’Hooghe’s et al. results. Specifically, they presented data 
on women previously operated for endometriosis who subsequently performed IUI and compared 
the rate of recurrence between those performing IUI on natural cycle and then ovarian stimulation 
(n=45) to those receiving straight only IUI with ovarian stimulation (n=20). The cumulative risk of 
recurrence was 35% and 72%, respectively (p=0.03). The adjusted Hazard Risk (HR) was 2.2 
(95%CI: 0.9-5.3). Albeit indirect, this result supports a detrimental effect of ovarian stimulation. 
 
Comparative studies 
Two non-randomized studies compared women with endometriosis receiving IVF to a control group 
of women with the disease who did not receive ART (Coccia et al. 2010; Crochet et al., 2016). 
Coccia et al. (2010) retrospectively identified 177 women who were operated for endometriosis and 
who were infertile and compared the rate of disease recurrence between those who did (n=90) and 
did not (n=87) undergo ART (both IVF and IUI). Forty recurrences were diagnosed, of whom 18 
were recorded in the ART group (20%) and the remaining 22 in the non-ART group (25%) (p=ns). 
The IVF group did not face a higher risk: ever users of IVF (i.e. combining women receiving IVF 
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and those receiving both IVF and IUI) had a recurrence rate of 19% (13 out of 70) (Coccia et al. 
2010). A multivariate analysis to adjust for the differences in baseline characteristics among the 
study groups was not performed. 
Albeit also comparative, insights from the study of Crochet et al. (2016) are difficult to interpret. 
These authors exclusively recruited women who were operated twice for endometriosis and 
compared modifications of the anatomical lesions at second surgery between women who had 
(n=21) and did not have (n=36) IVF in the interval between the two interventions. They actually 
failed to observe significant differences in the change of the ASRM score (Crochet et al., 2016). 
Unfortunately, the study did not report whether women undergoing IVF were more or less likely to 
be operated.  
Two studies aimed at overcoming the intrinsic difficulties of comparative studies using alternative 
methodological approaches (Benaglia et al., 2010; van der Houwen et al., 2014a). Benaglia et al. 
(2010) retrospectively identified 189 women with endometriosis who underwent IVF and actively 
investigated whether or not they had recurrences in the following years (the median time of follow-
up was 34 months). Specifically, they evaluated the impact of the number of cycles and the 
responsiveness to ovarian stimulation, based on the assumption that if a detrimental effect of IVF 
did exist, a gradient effect (an increase in the rate of recurrence with the number of IVF cycles and 
the responsiveness to treatment) would have emerged. No gradient effect was found. The adjusted 
OR of recurrences was 0.92 (95%CI: 0.77-1.10) per cycle and 0.80 (95% 0.40-1.58) for normal 
responders compared to poor responders (Benaglia et al., 2010). In the second study, van der 
Houwen et al. (2014a) hypothesized that, if a detrimental effect of IVF did exist, a lower risk of 
recurrences in women receiving long term down regulation with GnRH agonists prior to initiate the 
ovarian stimulation should be expected (ultralong protocol). They retrospectively recruited women 
with endometriosis who underwent IVF and compared the recurrence rate at 12 months between 
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women who did (n=68) and did not (n=45) receive the ultralong protocol. The adjusted OR for 
those who did receive this protocol was 0.95 (95%CI: 0.37-2.44) (van der Houwen et al., 2014a). 
 
Pain symptoms modifications 
Endometriosis recurrence and pain symptoms modifications are frequently associated, but should be 
considered distinct aspects. Three independent  prospective studies monitored pain symptoms 
during IVF cycles and all failed to observe detrimental effects (Benaglia et al. 2011; van der 
Houwen et al., 2014c; Santulli et al., 2016).  
Specifically, Benaglia et al. (2011) evaluated women with endometriosis prior to initiating the cycle 
and re-evaluated those who failed to become pregnant 3-6 months later. Sixty-four women were 
eventually assessed. Before-after intra-patient comparisons of the severity of dysmenorrhea, 
dyspareunia and non-menstrual pelvic pain failed to document significant differences. General 
improvement or worsening of symptoms was reported by 14 (22%) and 7 (11%) women, 
respectively. The vast majority (n=43;  67%) subjectively judged their symptoms as unchanged 
(Benaglia et al., 2011).  
Van der Houwen et al. enrolled 75 women with a surgical diagnosis of endometriosis stage III-IV 
prior to initiate IUI (n=25), classical IVF (n=25) and IVF with an ultra-long protocol (n=25) (Van 
der Houwen et al., 2014c). The rate of satisfaction did not differ among the three groups. For the 
whole cohort, the number (%) of women with improvement or deterioration of visual analogue 
scores (VAS)  according the studied symptom were as follows: dysmenorrhea 7 (23%) and 8 (26%); 
dyspareunia 7 (14%) and 5 (10%); non-menstrual pain 9 (13%) and 10 (15%); dyschesia 8 (12%) 
and 9 (13%); and dysuria 4 (6%) and 4 (6%), respectively. Moreover, no statistically significant 
differences emerged when comparing the three different study groups (Van der Houwen et al., 
2014c).     
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Santulli et al. prospectively compared 102 women with endometriosis and 104 unaffected women 
during an IVF cycle (Santulli et al., 2016). Four time-points were scheduled, i.e. prior to initiate 
oral contraceptive synchronization, during oral contraceptive synchronization, at the time of oocytes 
retrieval and three weeks later. At all time-points, the scores of dysmenorrhea, dyspareunia, non-
menstrual pain, and gastrointestinal symptoms were higher in affected women. However, compared 
to the baseline evaluation, pain increased during IVF in the control group, but not in the 
endometriosis group. The authors also performed a subgroup analysis according to the phenotype 
(superficial endometriosis, ovarian endometriomas or deep invasive endometriosis) but failed to 
identify a subgroup that was more sensitive to the IVF effects (Santulli et al., 2016).  
 
Lesions growth 
Superficial endometriosis cannot be monitored without performing a laparoscopy before and after 
the IVF cycle, a study design that is obviously ethically untenable. On the other hand, non-invasive 
diagnosis of ovarian endometriomas and deep invasive peritoneal lesions has become highly 
reliable (Guerriero et al., 2016; Nisenblat et al., 2016) and monitoring these lesions during IVF is 
feasible. Three studies reported data on US evaluation of ovarian endometriomas (Benaglia et al., 
2009; Benaglia et al., 2011; Seyhan et al., 2018), one of which provided data also on deep invasive 
lesions (Benaglia et al., 2011). 
Specifically, Benaglia et al. evaluated 48 women with a total of 70 ovarian endometriomas before 
and 3-6 months after a failed IVF cycle (women becoming pregnant were excluded) (Benaglia et 
al., 2009). The median (interquartile range - IQR) volume of the cysts before and after the cycle 
was 3.9 (2.9-7.9) and 4.9 (2.4-9.9) ml, respectively (p=ns). Subgroup analyses according to the 
dimension of the cyst and the responsiveness to ovarian stimulation failed to identify a subgroup at 
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higher risk of significant growth. One woman was diagnosed with an additional endometrioma at 
the second evaluation (2.1%, 95%CI: 0.1-11.1%) (Benaglia et al., 2009).  
Two years later, the same study group performed a second study that focused on symptoms 
modification before and 3-6 months after a failed IVF cycle (this study was already discussed in the 
previous chapter) (Benaglia et al., 2011). As secondary findings, the authors reported data also on 
endometriomas (35 women with 45 cysts) and deep invasive endometriosis (9 women with 10 
lesions) modifications. The median (IQR) diameter of the endometriomas before and after the cycle 
was 20 (12-27) and 20 (17-27) mm, respectively (p=ns).  The median (IQR) diameter of the deep 
lesions before and after the cycle was 10 (5-18) and 10 (5-18) mm, respectively (p=ns) (Benaglia et 
al., 2011). 
Finally, Seyhan et al. (2018) recently monitored ovarian endometrioma modification during the 
cycle using 3D ultrasound. Specifically, they evaluated the dimension of the cysts on the day of the 
initiation of ovarian stimulation and on the day of ovulation trigger in 25 women with 28 cysts. The 
volume increased from 22 (IQR: 12 - 30) mL to 25 (IQR: 11 - 37) mL (p<0.001), corresponding to 
a median increase of 14%. The authors showed a significant positive correlation between 
endometrioma growth and the baseline dimension of the endometriomas, but failed to detect any 
correlation with responsiveness to stimulation (Seyhan et al., 2018).  
 
Summary of the evidence 
The main conclusions that can be drawn from this systematic review are summarized in Table 3. 
Overall, the available evidence is not of high quality, and further data is needed to depict a 
definitive and comprehensive scenario.  
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The impact of IVF on endometriosis-related pain symptoms and on ovarian endometriomas are the 
most properly studied issues. They were both investigated with at least two independent prospective 
studies. However, data is not fully consistent. Even if the observational studies on pain symptoms 
failed to identify detrimental effects (moderate quality evidence), one cannot exclude that pain 
worsening may occur in some particular cases. The five women experiencing pain worsening during 
ovarian stimulation described by Jun and Lathi (2007) support this possibility. 
Considering endometriomas, IVF does not appear to markedly modify their dimension but data is 
not univocal. Indeed, two studies of the same study group did not report changes, while the third 
and independent one observed a mild but statistically significant increase in size. One can generally 
conclude that the impact of IVF on endometriomas dimension is modest, if any, but further 
evidence is needed and the quality evidence is inevitably rated as low. 
Data on the unremarkable effects of IVF on the rate of recurrences and those on the detrimental 
effects of IUI are supported by independent studies but the study designs have some limitations (in 
particular, none was prospective) and data is not univocal for IUI. Quality of the evidence can 
ultimately be rated as moderate and low for IVF and IUI, respectively.  
Finally, it is noteworthy that the possible progression of deep invasive endometriosis, which is 
actually the most worrying potential drawback of ovarian stimulation, is supported exclusively by 
case reports (very low quality evidence). Future data on this issue is needed.   
 
DISCUSSION 
Available evidence on the impact of ovarian stimulation and ARTs on endometriosis progression or 
recurrence is incomplete. None of the evidence could be graded as high quality. To note, this 
systematic review focused on observational studies and is consequently exposed to the risk of 
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publication bias. Some studies could have been missed because search filters for observational 
studies do not have the high sensitivity as search filters for RCTs. Moreover, the natural tendency of 
endometriosis to recur (Guo, 2009) complicates the interpretation of the findings because of the 
inherent difficulty of discerning between recurrences that are caused by stimulation and those that 
just coincidentally occurred after ARTs. Nonetheless, some notions have emerged and should 
deserve consideration in clinical practice. In particular, the reassuring data on the impact of IVF on 
endometriosis recurrence or pain-symptoms progression are supported by moderate quality 
evidence. Moreover, the impact on endometriomas’ dimension (if any) may be clinically 
unremarkable. This information can be used to reassure affected women entering an IVF program 
who may be concerned by the theoretical risks of ovarian stimulation.  
On the other hand, the insufficient data regarding deep invasive lesions is the most important 
scientific gap that needs to be covered in the future. These lesions are indeed particularly sensitive 
to oestrogens compared to other forms of the disease (Vercellini et al., 2016). Evidence from case 
reports and the high rate of deep invasive lesions observed among recurrent cases (71%, 95%CI: 
52-86%) fuel this concern. To date, however,  evidence is too scanty to support a detrimental effect. 
To note, despite the small sample size (only 9 women), the prospective study from Benaglia et al. 
(2011) failed to document a significant growth of these lesions. Moreover, there is a clear 
contradiction between the worrying case reports on deep invasive endometriosis published in the 
literature and the reassuring evidence emerging from case-series and cohort studies for 
endometriosis in general. On these bases, prophylactic surgery in women with deep invasive 
endometriosis to prevent progression seems to us unsubstantiated and probably unwise. Surgery for 
deep invasive endometriosis is technically demanding and potentially harmful (Kondo et al., 2011; 
Oliveira et al., 2016). It could be justified only based on robust clinical evidence. In this regard, it is 
also worth noting that there is no evidence to support a benefit of prophylactic surgery in terms of 
pregnancy rate after ART (Somigliana and Garcia-Velasco, 2015; Darai et al., 2017; Iversen et al., 
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2017). Surgery may be currently considered to increase the chances of pregnancy only if IVF fails 
(Littman et al., 2005).    
 The possible detrimental effects of IUI and the absence of effects of IVF is the most 
intriguing and unexpected finding of our review. Given the lower peripheral steroids and the lower 
number of developed follicles that are generally achieved in IUI compared to IVF cycles, the 
opposite findings would have been more logical. D’Hooghe et al. (2006) and van der Houwen et al. 
(2014b), who highlighted this increased risk, speculated that “the monthly exposure to ovulation 
and retrograde menstruation is the basis for the increased risk of endometriosis recurrence, which 
might be facilitated by ovarian hyper-stimulation”. If this is so, at least a similar effect for IVF 
should be expected, but this was not the case. To note, the available studies investigating the 
possible gradient effect between ovarian responsiveness (including oestrogens peak levels) and 
recurrence failed to identify any relation (D’Hooghe et al., 2006; Benaglia et al., 2009; Benaglia et 
al., 2010; Seyhan et al., 2018). An alternative explanation that refers to the origin of endometriomas 
can be suggested. Indeed, according to the ovulation theory, these cysts would develop from the 
corpus luteum invasion of endometriotic cells (Vercellini et al., 2010), an event that can be possible 
only when the ovulation stigma occurs in correspondence of the implant. In fact, this 
correspondence may be more likely in IUI cycles because endometriotic implants cause a local 
inflammation and many molecules involved in endometriosis-related inflammation are also 
involved in the process of ovulation dehiscence (Gérard et al., 2004; Somigliana et al., 2012). 
Ovulation may be somehow guided to occur in the proximity of superficial implants.  Conversely, 
in IVF, follicles are arbitrarily punctured and aspirated before spontaneous ovulation occurs. This 
interpretation is intriguing but speculative. One should at least disentangle whether the reported 
IUI-related recurrence is specific, i.e. mostly consisting in endometriomas rather than other lesions. 
Unfortunately, the available evidence did not differentiate between ovarian and non-ovarian lesions 
(D'Hooghe et al., 2006; Coccia et al. 2010; van der Houwen et al., 2014b). Finally, a third possible 
17 
 
interpretation of the increased risk in IUI cycles may be related to the confounding effect of time. 
Indeed, women who undergo IUI simply allow more time to pass than if they had moved straight to 
IVF. This passage of time (fertility interventions or not) would naturally result in a higher rate of 
recurrences.    
 From a clinical perspective, the alarmism on the possible detrimental effects of IUI is of 
debatable relevance. In fact, the clinical utility of IUI in infertile women with endometriosis is 
questionable for several reasons. Firstly, albeit debated, the recent NICE guideline does not 
consider IUI for the group of women with unexplained infertility (that includes also women with 
endometriosis stage I-II) (Bahadur et al. 2015; NICE, 2013). Secondly, specific evidence in favour 
of IUI for women with endometriosis is weak (Somigliana et al., 2017). Last but not least, there is 
no rationale for IUI in women with endometriosis. The detrimental effects of the disease on fertility 
are mainly due to intraperitoneal effects, i.e. anatomic distortion due to adherences and the 
development of an unfavourable peritoneal milieu that may affect gametes and early embryos 
(Somigliana et al., 2017). In this context, IUI cannot be expected to provide any benefit.  
 The general reassuring scenario emerging from our review has important clinical 
implications but also warrants some pathogenic comments. Endometriosis is actually an oestrogen-
dependent disease and the unremarkable effects of IVF is somehow surprising. There is strong 
evidence that oestrogens exposure may facilitate endometriosis growth. Accordingly, lowering 
serum oestrogens is still the crucial target of modern medical therapy of endometriosis (Vercellini et 
al., 2016; Taylor et al., 2017). This conceptual inconsistency is difficult to explain. On the other 
hand, the syllogism linking oestrogens dependence of endometriosis to a detrimental effect of IVF 
due to the marked raise in oestrogens is presumably too simplistic. In our opinion, the most 
plausible explanation is related to the duration of the exposure. Peripheral oestrogens do raise 
significantly during ovarian stimulation, reaching levels that are up to 10 folds higher (2-4,000 
pg/ml) than those occurring in natural cycles. However, these levels are reached only for a few days 
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and, immediately after the oocytes retrieval, progesterone level typically raise considerably 
(Macklon et al., 2006). It may be speculated that this may effectively and promptly counteract the 
previous short term detrimental effects of hyper-oestrogenism. To note, high-dose progesterone is 
also commonly prescribed after ovarian stimulation to support the luteal phase (van der Linden et 
al., 2011). 
 In this study, we aimed exclusively at disentangling the possible effects of ovarian 
stimulation on endometriosis. We were not interested in the pregnancy-related effects on the disease 
and, therefore, we excluded studies reporting complications of endometriosis occurring during 
pregnancy in women conceiving with ARTs. This choice may be viewed as a limitation of our 
review, but was based on the difficulty (impossibility) to disentangle the effects of ovarian 
stimulation and those of pregnancy. On the other hand, it cannot be excluded that the mild (if any) 
effects of ovarian stimulation could be boosted by the additional effects of pregnancy. In other 
words, the ovarian stimulation might be a predisposing condition favouring the detrimental effects 
of pregnancy. Indeed, even if pregnancy is historically considered beneficial to endometriosis 
(McArthur and Ulfelder, 1965), in rare and still unexplained cases, the disease may unexpectedly 
and rapidly progresses leading to severe and potentially fatal complications such as spontaneous 
haemoperitoneum (Brosens et al., 2016; Leone Roberti Maggiore et al., 2016; Leone Roberti 
Maggiore et al., 2017). In a systematic review of the literature on this frightful complication, 
Brosens et al. (2016) showed that 24 out of the 64 described cases (38%) occurred in women with 
endometriosis undergoing ovarian stimulation. It remains to be clarified whether this observation 
reflects a real detrimental effect of IVF or, conversely, whether it is just consequent to the fact that 
worse endometriosis cases require more frequently IVF (Vercellini et al., 2018). 
 In this regard, it has also to be pointed out that, independently of disease progression or pain 
symptom recurrence after ovarian stimulation, performance of IVF in infertile women with severe, 
deep endometriosis poses an ethical issue, because most of these women would not get pregnant 
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without this technique. Therefore, as IVF is an active medical intervention, discussion of its 
potential harms should not be limited to the impact on endometriosis, but should address also 
possible obstetrical sequelae, including not only spontaneous haemoperitoneum, but also the 
increased risk of placenta praevia and the reportedly high complication rate associated with a 
caesarean delivery in women with severely distorted abdomino-pelvic anatomy (Vercellini et al., 
2018). This appears important because, when thoroughly informed, some women may even decide 
not to undergo IVF (Somigliana et al., 2015b). 
 
CONCLUSIONS 
Even if there is growing agreement on the central role of ARTs in the management of 
endometriosis-related infertility, several issues remain disputed. Of particular relevance is the 
relative role of surgery and ART. In general, definitive evidence is not available and a shared 
decision-making approach with the woman is mandatory. The counselling should be comprehensive 
and exhaustive and the reassuring evidence emerging from this review should be part of this 
discussion. Nonetheless, the debate on the detrimental effects of ovarian stimulation on 
endometriosis progression is yet open. In particular, the potential effects on deep invasive 
endometriosis and the possible synergic effects of pregnancy are two arguments that need to be 
urgently explored.   
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Figure legend 
 
Figure 1: Flow chart of the study. Sixteen studies were ultimately included, of whom four were 
case reports. 
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